<- Go Home
Mayne Pharma Group Limited
Mayne Pharma Group Limited, a specialty pharmaceutical company, focuses on the commercialization of women’s health and dermatology pharmaceuticals in Australia, New Zealand, the United States, Canada, Europe, Asia, and internationally. It operates through three segments: Women’s Health, Dermatology, and International. The company provides oral drug delivery systems, as well as contract development and manufacturing services to third-party customers. It also distributes specialty pharmaceutical products in the dermatology, women’s health, and infectious disease therapeutic areas. The company was formerly known as Halcygen Pharmaceuticals Limited and changed its name to Mayne Pharma Group Limited in November 2010. Mayne Pharma Group Limited was incorporated in 2005 and is based in Salisbury South, Australia.
Market Cap
AUD 501.3M
Volume
436.9K
Cash and Equivalents
AUD 59.8M
EBITDA
AUD 42.1M
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
AUD 247.3M
Profit Margin
60.59%
52 Week High
AUD 7.31
52 Week Low
AUD 4.02
Dividend
N/A
Price / Book Value
1.35
Price / Earnings
-5.41
Price / Tangible Book Value
-2.92
Enterprise Value
AUD 442.2M
Enterprise Value / EBITDA
9.68
Operating Income
-AUD 22.0M
Return on Equity
21.85%
Return on Assets
-1.28
Cash and Short Term Investments
AUD 100.4M
Debt
AUD 41.3M
Equity
AUD 370.3M
Revenue
AUD 408.1M
Unlevered FCF
AUD 1.7M
Sector
Pharmaceuticals
Category
N/A
Hedge Funds that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Professional Funds that own this company (and many other perks).
Upgrade to Yellowbrick PremiumYellowbrick Portfolios that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Yellowbrick portfolios that own this company (and many other perks).
Upgrade to Yellowbrick Premium